OBJECTIVE: The need of today's research is to develop successful and reliable diabetic animal models for understanding the disease susceptibility and pathogenesis. Enormous success of animal models had already been acclaimed for identifying key genetic and environmental factors like Idd loci and effects of microorganisms including the gut microbiota. Furthermore, animal models had also helped in identifying many therapeutic targets and strategies for immune-intervention. In spite of a quite success, we have acknowledged that many of the discovered immunotherapies are working on animals and did not have a significant impact on human. Number of animal models were developed in the past to accelerate drug discovery pipeline. However, due to poor initial screening and assessment on inequivalent animal models, the percentage of drug candidates who succeeded during clinical trials was very low. Therefore, it is essential to bridge this gap between pre-clinical research and clinical trial by validating the existing animal models for consistency. RESULTS AND CONCLUSION: In this review, we have discussed and evaluated the significance of animal models on behalf of published data on PUBMED. Amongst the most popular diabetic animal models, we have selected six animal models (e.g. BioBreeding rat, "LEW IDDM rat", "Nonobese Diabetic (NOD) mouse", "STZ RAT", "LEPR Mouse" and "Zucker Diabetic Fatty (ZDF) rat" and ranked them as per their published literature on PUBMED. Moreover, the vision and brief imagination for developing an advanced and robust diabetic model of 21st century was discussed with the theme of one miceone human concept including organs-on-chips.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Physiology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Ericsson A.C., Crim M.J., Franklin C.L. A brief history of animal modeling. Mo. Med. 2013;110(3):201–205. [PMID: 23829102]. PubMed PMC

Denayer T., Stöhr T., Van Roy M. Animal models in translational medicine: Validation and prediction. New Horiz. Transl. Med. 2014;2(1):5–11. [http://dx.doi.org/10.1016/j.nhtm.2014.08.001].

Balls M. The wisdom of Russell and Burch. 3. Fidelity and discrimination. Altern. Lab. Anim. 2013;41(1):12–14. [http://dx.doi.org/10.1177/026119291304100120]. [PMID: 23614551]. PubMed

Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents. 2002;19(4):261–268. [http://dx.doi.org/10.1016/S0924-8579(02)00022-5]. [PMID: 11978497]. PubMed

Zhao M., Lepak A.J., Andes D.R. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg. Med. Chem. 2016;24(24):6390–6400. [http://dx.doi.org/10.1016/j.bmc.2016.11.008]. [PMID: 27887963]. PubMed

McGonigle P., Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem. Pharmacol. 2014;87(1):162–171. [http://dx.doi.org/10.1016/j.bcp.2013.08.006]. [PMID: 23954708]. PubMed

Vaddady P.K., Lee R.E., Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med. Chem. 2010;2(8):1355–1369. [http://dx.doi.org/10.4155/fmc.10.224]. [PMID: 21359155]. PubMed PMC

Brochot A., Zamacona M., Stockis A. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. Basic Clin. Pharmacol. Toxicol. 2010;106(3):256–262. [http://dx.doi.org/10.1111/j.1742-7843.2009.00536.x]. [PMID: 20102365]. PubMed

Lodise T.P., Drusano G.L. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin. Infect. Dis. 2014;58(Suppl. 1):S28–S34. [http://dx.doi.org/10.1093/cid/cit615]. [PMID: 24343829]. PubMed

Ogurtsova K., da Rocha Fernandes J.D., Huang Y., Linnenkamp U., Guariguata L., Cho N.H., Cavan D., Shaw J.E., Makaroff L.E. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract. 2017;128:40–50. [http://dx.doi.org/10.1016/j.diabres.2017.03.024]. [PMID: 28437734]. PubMed

Rowley W.R., Bezold C., Arikan Y., Byrne E., Krohe S. Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul. Health Manag. 2017;20(1):6–12. [http://dx.doi.org/10.1089/pop.2015.0181]. [PMID: 27124621]. PubMed PMC

Roden M. Wien. Klin. Wochenschr. 2016;128(Suppl. 2):S37–S40. [Diabetes mellitus: definition, classification and diagnosis]. [Diabetes mellitus: definition, classification and diagnosis]. [http://dx.doi.org/10.1007/s00508-015-0931-3]. [PMID: 27052219]. PubMed

Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221–229. [http://dx.doi.org/10.1016/S0140-6736(01)05415-0]. [PMID: 11476858]. PubMed

Nyaga D.M., Vickers M.H., Jefferies C., Perry J.K., O’Sullivan J.M. The genetic architecture of type 1 diabetes mellitus. Mol. Cell. Endocrinol. 2018;477:70–80. [http://dx.doi.org/10.1016/j.mce.2018.06.002]. [PMID: 29913182]. PubMed

Redondo M.J., Fain P.R., Eisenbarth G.S. Genetics of type 1A diabetes. Recent Prog. Horm. Res. 2001;56:69–89. [http://dx.doi.org/10.1210/rp.56.1.69]. [PMID: 11237226]. PubMed

Kelly M.A., Mijovic C.H., Barnett A.H. Genetics of type 1 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 2001;15(3):279–291. [http://dx.doi.org/10.1053/beem.2001.0146]. [PMID: 11554771]. PubMed

Slavikova J., Mistrova E., Dvorakova M.C. Pathophysiology of diabetic cardiomyopathy. Diabetologie Metabolismus Endokrinologie Vyziva. 2018;21(1):21–29.

DeFronzo R.A., Ferrannini E., Groop L., Henry R.R., Herman W.H., Holst J.J., Hu F.B., Kahn C.R., Raz I., Shulman G.I., Simonson D.C., Testa M.A., Weiss R. Type 2 diabetes mellitus. Nat. Rev. Dis. Primers. 2015;1:15019. [http://dx.doi.org/10.1038/nrdp.2015.19]. [PMID: 27189025]. PubMed

Murai Y., Ohta T., Tadaki H., Miyajima K., Shinohara M., Fatchiyah F., Yamada T. Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model. Med. Arh. 2017;71(6):380–384. [http://dx.doi.org/10.5455/medarh.2017.71.380-384]. [PMID: 29416195]. PubMed PMC

Al-Awar A., Kupai K., Veszelka M., Szűcs G., Attieh Z., Murlasits Z., Török S., Pósa A., Varga C. Experimental Diabetes Mellitus in Different Animal Models. J. Diabetes Res. 2016;•••:20169051426. [http://dx.doi.org/10.1155/2016/9051426]. [PMID: 27595114]. PubMed PMC

Srinivasan K., Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 2007;125(3):451–472. [PMID: 17496368]. PubMed

King A.J. The use of animal models in diabetes research. Br. J. Pharmacol. 2012;166(3):877–894. [http://dx.doi.org/10.1111/j.1476-5381.2012.01911.x]. [PMID: 22352879]. PubMed PMC

Sasase T., Pezzolesi M.G., Yokoi N., Yamada T., Matsumoto K. Animal models of diabetes and metabolic disease. J. Diabetes Res. 2013;•••:2013281928. [http://dx.doi.org/10.1155/2013/281928]. [PMID: 23878821]. PubMed PMC

Mordes J.P., Bortell R., Blankenhorn E.P., Rossini A.A., Greiner D.L. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J. 2004;45(3):278–291. [http://dx.doi.org/10.1093/ilar.45.3.278]. [PMID: 15229375]. PubMed

Rees D.A., Alcolado J.C. Animal models of diabetes mellitus. Diabet. Med. 2005;22(4):359–370. [http://dx.doi.org/10.1111/j.1464-5491.2005.01499.x]. [PMID: 15787657]. PubMed

Wallis R.H., Wang K., Marandi L., Hsieh E., Ning T., Chao G.Y., Sarmiento J., Paterson A.D., Poussier P. Type 1 diabetes in the BB rat: a polygenic disease. Diabetes. 2009;58(4):1007–1017. [http://dx.doi.org/10.2337/db08-1215]. [PMID: 19168599]. PubMed PMC

Holmberg R., Refai E., Höög A., Crooke R.M., Graham M., Olivecrona G., Berggren P.O., Juntti-Berggren L. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc. Natl. Acad. Sci. USA. 2011;108(26):10685–10689. [http://dx.doi.org/10.1073/pnas.1019553108]. [PMID: 21670290]. PubMed PMC

Hartoft-Nielsen M.L., Rasmussen A.K., Bock T., Feldt-Rasmussen U., Kaas A., Buschard K. Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats. Autoimmunity. 2009;42(2):131–138. [http://dx.doi.org/10.1080/08916930802438774]. [PMID: 19021014]. PubMed

Zhang W., Kamiya H., Ekberg K., Wahren J., Sima A.A. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes Metab. Res. Rev. 2007;23(1):63–70. [http://dx.doi.org/10.1002/dmrr.672]. [PMID: 16845685]. PubMed

Jörns A., Günther A., Hedrich H.J., Wedekind D., Tiedge M., Lenzen S. Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes. 2005;54(7):2041–2052. [http://dx.doi.org/10.2337/diabetes.54.7.2041]. [PMID: 15983205]. PubMed

Lenzen S., Tiedge M., Elsner M., Lortz S., Weiss H., Jörns A., Klöppel G., Wedekind D., Prokop C.M., Hedrich H.J. The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia. 2001;44(9):1189–1196. [http://dx.doi.org/10.1007/s001250100625]. [PMID: 11596676]. PubMed

Mathews C.E. Utility of murine models for the study of spontaneous autoimmune type 1 diabetes. Pediatr. Diabetes. 2005;6(3):165–177. [http://dx.doi.org/10.1111/j.1399-543X.2005.00123.x]. [PMID: 16109074]. PubMed

Jörns A., Rath K.J., Terbish T., Arndt T., Meyer Zu Vilsendorf A., Wedekind D., Hedrich H.J., Lenzen S. Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology. 2010;151(8):3555–3565. [http://dx.doi.org/10.1210/en.2010-0202]. [PMID: 20501676]. PubMed

Arndt T., Wedekind D., Weiss H., Tiedge M., Lenzen S., Hedrich H.J., Jörns A. Prevention of spontaneous immune-mediated diabetes development in the LEW.1AR1-iddm rat by selective CD8+ T cell transfer is associated with a cytokine shift in the pancreas-draining lymph nodes. Diabetologia. 2009;52(7):1381–1390. [http://dx.doi.org/10.1007/s00125-009-1348-1]. [PMID: 19367386]. PubMed

Jörns A., Kubat B., Tiedge M., Wedekind D., Hedrich H.J., Klöppel G., Lenzen S. Pathology of the pancreas and other organs in the diabetic LEW.1AR1/Ztm- iddm rat, a new model of spontaneous insulin-dependent diabetes mellitus. Virchows Arch. 2004;444(2):183–189. [http://dx.doi.org/10.1007/s00428-003-0956-2]. [PMID: 14735361]. PubMed

Peschke E., Hofmann K., Bähr I., Streck S., Albrecht E., Wedekind D., Mühlbauer E. The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia. 2011;54(7):1831–1840. [http://dx.doi.org/10.1007/s00125-011-2138-0]. [PMID: 21491159]. PubMed

Yang Z., Chen M., Fialkow L.B., Ellett J.D., Wu R., Brinkmann V., Nadler J.L., Lynch K.R. The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice. Clin. Immunol. 2003;107(1):30–35. [http://dx.doi.org/10.1016/S1521-6616(02)00054-2]. [PMID: 12738247]. PubMed

Maki T., Gottschalk R., Ogawa N., Monaco A.P. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation. 2005;79(9):1051–1055. [http://dx.doi.org/10.1097/01.TP.0000161220.87548.EE]. [PMID: 15880042]. PubMed

Hanafusa T., Miyagawa J., Nakajima H., Tomita K., Kuwajima M., Matsuzawa Y., Tarui S. The NOD mouse. Diabetes Res. Clin. Pract. 1994;(24):S307–S311. [http://dx.doi.org/10.1016/0168-8227(94)90267-4]. PubMed

Yoon J.W., Jun H.S. Viruses in type 1 diabetes: brief review. ILAR J. 2004;45(3):343–348. [http://dx.doi.org/10.1093/ilar.45.3.343]. [PMID: 15229381]. PubMed

Jansen A., Homo-Delarche F., Hooijkaas H., Leenen P.J., Dardenne M., Drexhage H.A. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes. 1994;43(5):667–675. [http://dx.doi.org/10.2337/diab.43.5.667]. [PMID: 8168644]. PubMed

Bouma G., Coppens J.M., Mourits S., Nikolic T., Sozzani S., Drexhage H.A., Versnel M.A. Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice. Eur. J. Immunol. 2005;35(8):2386–2396. [http://dx.doi.org/10.1002/eji.200526251]. [PMID: 16047341]. PubMed

Diana J., Simoni Y., Furio L., Beaudoin L., Agerberth B., Barrat F., Lehuen A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 2013;19(1):65–73. [http://dx.doi.org/10.1038/nm.3042]. [PMID: 23242473]. PubMed

Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009;155(2):173–181. [http://dx.doi.org/10.1111/j.1365-2249.2008.03860.x]. [PMID: 19128359]. PubMed PMC

Miyazaki A., Hanafusa T., Yamada K., Miyagawa J., Fujino-Kurihara H., Nakajima H., Nonaka K., Tarui S. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin. Exp. Immunol. 1985;60(3):622–630. [PMID: 3160515]. PubMed PMC

Pearson J.A., Wong F.S., Wen L. The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun. 2016;66:76–88. [http://dx.doi.org/10.1016/j.jaut.2015.08.019]. [PMID: 26403950]. PubMed PMC

Noble J.A., Erlich H.A. Genetics of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2012;2(1):a007732. [http://dx.doi.org/10.1101/cshperspect.a007732]. [PMID: 22315720]. PubMed PMC

Chen Y.G., Mathews C.E., Driver J.P. The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future. Front. Endocrinol. (Lausanne) 2018;9:51. [http://dx.doi.org/10.3389/fendo.2018.00051]. [PMID: 29527189]. PubMed PMC

Todd J.A., Wicker L.S. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity. 2001;15(3):387–395. [http://dx.doi.org/10.1016/S1074-7613(01)00202-3]. [PMID: 11567629]. PubMed

von Herrath M., Filippi C., Coppieters K. How viral infections enhance or prevent type 1 diabetes-from mouse to man. J. Med. Virol. 2011;83(9):1672. [http://dx.doi.org/10.1002/jmv.22063]. [PMID: 21739461]. PubMed

Yang Y., Santamaria P. Lessons on autoimmune diabetes from animal models. Clin. Sci. (Lond.) 2006;110(6):627–639. [http://dx.doi.org/10.1042/CS20050330]. [PMID: 16689681]. PubMed

Mathews C.E., Langley S.H., Leiter E.H. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation. 2002;73(8):1333–1336. [http://dx.doi.org/10.1097/00007890-200204270-00024]. [PMID: 11981430]. PubMed

Drel V.R., Pacher P., Stavniichuk R., Xu W., Zhang J., Kuchmerovska T.M., Slusher B., Obrosova I.G. Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. Int. J. Mol. Med. 2011;28(4):629–635. [PMID: 21617845]. PubMed PMC

Zhou C., Pridgen B., King N., Xu J., Breslow J.L. Hyperglycemic Ins2AkitaLdlr−/− mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. J. Lipid Res. 2011;52(8):1483–1493. [http://dx.doi.org/10.1194/jlr.M014092]. [PMID: 21606463]. PubMed PMC

Gurley S.B., Clare S.E., Snow K.P., Hu A., Meyer T.W., Coffman T.M. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Renal Physiol. 2006;290(1):F214–F222. [http://dx.doi.org/10.1152/ajprenal.00204.2005]. [PMID: 16118394]. PubMed

Tyrberg B., Andersson A., Borg L.A. Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta-cell toxin alloxan. Gen. Comp. Endocrinol. 2001;122(3):238–251. [http://dx.doi.org/10.1006/gcen.2001.7638]. [PMID: 11356036]. PubMed

Dufrane D., van Steenberghe M., Guiot Y., Goebbels R.M., Saliez A., Gianello P. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation. 2006;81(1):36–45. [http://dx.doi.org/10.1097/01.tp.0000189712.74495.82]. [PMID: 16421474]. PubMed

Eizirik D.L., Pipeleers D.G., Ling Z., Welsh N., Hellerström C., Andersson A. Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc. Natl. Acad. Sci. USA. 1994;91(20):9253–9256. [http://dx.doi.org/10.1073/pnas.91.20.9253]. [PMID: 7937750]. PubMed PMC

Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51(2):216–226. [http://dx.doi.org/10.1007/s00125-007-0886-7]. [PMID: 18087688]. PubMed

Wise M.H., Gordon C., Johnson R.W. Intraportal autotransplantation of cryopreserved porcine islets of Langerhans. Cryobiology. 1985;22(4):359–366. [http://dx.doi.org/10.1016/0011-2240(85)90183-X]. [PMID: 3161702]. PubMed

He S., Chen Y., Wei L., Jin X., Zeng L., Ren Y., Zhang J., Wang L., Li H., Lu Y., Cheng J. Treatment and risk factor analysis of hypoglycemia in diabetic rhesus monkeys. Exp. Biol. Med. (Maywood) 2011;236(2):212–218. [http://dx.doi.org/10.1258/ebm.2010.010208]. [PMID: 21321318]. PubMed

Wei L., Lu Y., He S., Jin X., Zeng L., Zhang S., Chen Y., Tian B., Mai G., Yang G., Zhang J., Wang L., Li H., Markmann J.F., Cheng J., Deng S. Induction of diabetes with signs of autoimmunity in primates by the injection of multiple-low-dose streptozotocin. Biochem. Biophys. Res. Commun. 2011;412(2):373–378. [http://dx.doi.org/10.1016/j.bbrc.2011.07.105]. [PMID: 21821007]. PubMed

Moon C.H., Jung Y.S., Lee S.H., Baik E.J. Protein kinase C inhibitors abolish the increased resistance of diabetic rat heart to ischemia-reperfusion injury. Jpn. J. Physiol. 1999;49(5):409–415. [http://dx.doi.org/10.2170/jjphysiol.49.409]. [PMID: 10603424]. PubMed

Chen H., Shen W.L., Wang X.H., Chen H.Z., Gu J.Z., Fu J., Ni Y.F., Gao P.J., Zhu D.L., Higashino H. Paradoxically enhanced heart tolerance to ischaemia in type 1 diabetes and role of increased osmolarity. Clin. Exp. Pharmacol. Physiol. 2006;33(10):910–916. [http://dx.doi.org/10.1111/j.1440-1681.2006.04463.x]. [PMID: 17002667]. PubMed

Ravingerova T., Matejikova J., Pancza D., Kolar F. Reduced susceptibility to ischemia-induced arrhythmias in the preconditioned rat heart is independent of PI3-kinase/Akt. Physiol. Res. 2009;58(3):443–447. [PMID: 19627174]. PubMed

Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., Lakey N.D., Culpepper J., Moore K.J., Breitbart R.E., Duyk G.M., Tepper R.I., Morgenstern J.P. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491–495. [http://dx.doi.org/10.1016/S0092-8674(00)81294-5]. [PMID: 8608603]. PubMed

Gault V.A., Kerr B.D., Harriott P., Flatt P.R. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin. Sci. (Lond.) 2011;121(3):107–117. [http://dx.doi.org/10.1042/CS20110006]. [PMID: 21332446]. PubMed

Yoshida S., Tanaka H., Oshima H., Yamazaki T., Yonetoku Y., Ohishi T., Matsui T., Shibasaki M. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Biochem. Biophys. Res. Commun. 2010;400(4):745–751. [http://dx.doi.org/10.1016/j.bbrc.2010.08.141]. [PMID: 20816753]. PubMed

Park J.S., Rhee S.D., Kang N.S., Jung W.H., Kim H.Y., Kim J.H., Kang S.K., Cheon H.G., Ahn J.H., Kim K.Y. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344). Biochem. Pharmacol. 2011;81(8):1028–1035. [http://dx.doi.org/10.1016/j.bcp.2011.01.020]. [PMID: 21315688]. PubMed

Lindström P. The physiology of obese-hyperglycemic mice. ScientificWorldJournal. 2007;7:666–685. [ob/ob mice]. [ob/ob mice]. [http://dx.doi.org/10.1100/tsw.2007.117]. [PMID: 17619751]. PubMed PMC

Chehab F.F., Lim M.E., Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat. Genet. 1996;12(3):318–320. [http://dx.doi.org/10.1038/ng0396-318]. [PMID: 8589726]. PubMed

Bock T., Pakkenberg B., Buschard K. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes. 2003;52(7):1716–1722. [http://dx.doi.org/10.2337/diabetes.52.7.1716]. [PMID: 12829638]. PubMed

Lavine R.L., Voyles N., Perrino P.V., Recant L. Functional abnormalities of islets of Langerhans of obese hyperglycemic mouse. Am. J. Physiol. 1977;233(2):E86–E90. [PMID: 329686]. PubMed

Coleman D.L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978;14(3):141–148. [http://dx.doi.org/10.1007/BF00429772]. [PMID: 350680]. PubMed

Asensio C., Cettour-Rose P., Theander-Carrillo C., Rohner-Jeanrenaud F., Muzzin P. Changes in glycemia by leptin administration or high- fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis. Endocrinology. 2004;145(5):2206–2213. [http://dx.doi.org/10.1210/en.2003-1679]. [PMID: 14962997]. PubMed

Zhang B., Salituro G., Szalkowski D., Li Z., Zhang Y., Royo I., Vilella D., Díez M.T., Pelaez F., Ruby C., Kendall R.L., Mao X., Griffin P., Calaycay J., Zierath J.R., Heck J.V., Smith R.G., Moller D.E. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science. 1999;284(5416):974–977. [http://dx.doi.org/10.1126/science.284.5416.974]. [PMID: 10320380]. PubMed

Chakrabarti R., Vikramadithyan R.K., Misra P., Hiriyan J., Raichur S., Damarla R.K., Gershome C., Suresh J., Rajagopalan R. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br. J. Pharmacol. 2003;140(3):527–537. [http://dx.doi.org/10.1038/sj.bjp.0705463]. [PMID: 12970088]. PubMed PMC

Hummel K.P., Dickie M.M., Coleman D.L. Diabetes, a new mutation in the mouse. Science. 1966;153(3740):1127–1128. [http://dx.doi.org/10.1126/science.153.3740.1127]. [PMID: 5918576]. PubMed

Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.J., Hess J.F. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 1996;13(1):18–19. [http://dx.doi.org/10.1038/ng0596-18]. [PMID: 8673096]. PubMed

Tokuyama Y., Sturis J., DePaoli A.M., Takeda J., Stoffel M., Tang J., Sun X., Polonsky K.S., Bell G.I. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995;44(12):1447–1457. [http://dx.doi.org/10.2337/diab.44.12.1447]. [PMID: 7589853]. PubMed

Lee Y., Hirose H., Zhou Y.T., Esser V., McGarry J.D., Unger R.H. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes. 1997;46(3):408–413. [http://dx.doi.org/10.2337/diab.46.3.408]. [PMID: 9032096]. PubMed

Shimabukuro M., Zhou Y.T., Levi M., Unger R.H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc. Natl. Acad. Sci. USA. 1998;95(5):2498–2502. [http://dx.doi.org/10.1073/pnas.95.5.2498]. [PMID: 9482914]. PubMed PMC

Shimabukuro M., Higa M., Zhou Y.T., Wang M.Y., Newgard C.B., Unger R.H. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J. Biol. Chem. 1998;273(49):32487–32490. [http://dx.doi.org/10.1074/jbc.273.49.32487]. [PMID: 9829981]. PubMed

Hemmes R.B., Schoch R. High dosage testosterone propionate induces copulatory behavior in the obese male Zucker rat. Physiol. Behav. 1988;43(3):321–324. [http://dx.doi.org/10.1016/0031-9384(88)90195-3]. [PMID: 3174844]. PubMed

Shibata T., Takeuchi S., Yokota S., Kakimoto K., Yonemori F., Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br. J. Pharmacol. 2000;130(3):495–504. [http://dx.doi.org/10.1038/sj.bjp.0703328]. [PMID: 10821776]. PubMed PMC

Clohessy J.G., Pandolfi P.P. Mouse hospital and co-clinical trial project--from bench to bedside. Nat. Rev. Clin. Oncol. 2015;12(8):491–498. [http://dx.doi.org/10.1038/nrclinonc.2015.62]. [PMID: 25895610]. PubMed

Clohessy J.G., Pandolfi P.P. The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care. Front. Oncol. 2018;8:340. [http://dx.doi.org/10.3389/fonc.2018.00340]. [PMID: 30211119]. PubMed PMC

Yang F., Stewart M., Ye J., DeMets D. Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes Metab. Syndr. Obes. 2015;8:315–325. [http://dx.doi.org/10.2147/DMSO.S84005]. [PMID: 26229496]. PubMed PMC

Brass E.P. The Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes. Diabetes Spectr. 2014;27(2):75–77. [http://dx.doi.org/10.2337/diaspect.27.2.75]. [PMID: 26246760]. PubMed PMC

Smith R.J., Goldfine A.B., Hiatt W.R. Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess? Diabetes Care. 2016;39(5):738–742. [http://dx.doi.org/10.2337/dc15-2237]. [PMID: 27208377]. PubMed

Garcia-Verdugo R., Erbach M., Schnell O. Need for Outcome Scenario Analysis of Clinical Trials in Diabetes. J. Diabetes Sci. Technol. 2017;11(2):327–334. [http://dx.doi.org/10.1177/1932296816670925]. [PMID: 27707913]. PubMed PMC

Derscheid R.J., Ackermann M.R. Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses. 2012;4(10):2359–2378. [http://dx.doi.org/10.3390/v4102359]. [PMID: 23202468]. PubMed PMC

Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov. Today. 2006;11(7-8):355–363. [http://dx.doi.org/10.1016/j.drudis.2006.02.005]. [PMID: 16580978]. PubMed

Cavagnaro J., Silva Lima B. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products. Eur. J. Pharmacol. 2015;759:51–62. [http://dx.doi.org/10.1016/j.ejphar.2015.03.048]. [PMID: 25814257]. PubMed

Pinger C.W., Entwistle K.E., Bell T.M., Liu Y., Spence D.M. C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment? Mol. Biosyst. 2017;13(8):1432–1437. [http://dx.doi.org/10.1039/C7MB00199A]. [PMID: 28685788]. PubMed PMC

Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007;356(24):2457–2471. [http://dx.doi.org/10.1056/NEJMoa072761]. [PMID: 17517853]. PubMed

Cheng D., Gao H., Li W. Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis. Endokrynol. Pol. 2018;69(4):381–394. [PMID: 29952413]. PubMed

Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189–1195. [http://dx.doi.org/10.1001/jama.298.10.1189]. [PMID: 17848653]. PubMed

Blind E., Dunder K., de Graeff P.A., Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia. 2011;54(2):213–218. [http://dx.doi.org/10.1007/s00125-010-1992-5]. [PMID: 21153629]. PubMed

Cummings J.L., Morstorf T., Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 2014;6(4):37. [http://dx.doi.org/10.1186/alzrt269]. [PMID: 25024750]. PubMed PMC

van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O’Collins V., Macleod M.R. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245. [http://dx.doi.org/10.1371/journal.pmed.1000245]. [PMID: 20361020]. PubMed PMC

Tyagi P., Pechenov S., Anand Subramony J. Oral peptide delivery: Translational challenges due to physiological effects. J. Control. Release. 2018;287:167–176. [http://dx.doi.org/10.1016/j.jconrel.2018.08.032]. [PMID: 30145135]. PubMed

Hooper S.B., Te Pas A.B., Polglase G.R., Wyckoff M. Animal models in neonatal resuscitation research: What can they teach us? Semin. Fetal Neonatal Med. 2018;23(5):300–305. [http://dx.doi.org/10.1016/j.siny.2018.07.002]. [PMID: 30001819]. PubMed

Koch J.C., Tatenhorst L., Roser A.E., Saal K.A., Tönges L., Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol. Ther. 2018;189:1–21. [http://dx.doi.org/10.1016/j.pharmthera.2018.03.008]. [PMID: 29621594]. PubMed

Eicher A.K., Berns H.M., Wells J.M. Translating Developmental Principles to Generate Human Gastric Organoids. Cell. Mol. Gastroenterol. Hepatol. 2018;5(3):353–363. [http://dx.doi.org/10.1016/j.jcmgh.2017.12.014]. [PMID: 29552623]. PubMed PMC

Kenney L.L., Shultz L.D., Greiner D.L., Brehm M.A. Humanized Mouse Models for Transplant Immunology. Am. J. Transplant. 2016;16(2):389–397. [http://dx.doi.org/10.1111/ajt.13520]. [PMID: 26588186]. PubMed PMC

Wege A.K. Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy. BioDrugs. 2018;32(3):245–266. [http://dx.doi.org/10.1007/s40259-018-0275-4]. [PMID: 29589229]. PubMed

Ito R., Takahashi T., Katano I., Ito M. Current advances in humanized mouse models. Cell. Mol. Immunol. 2012;9(3):208–214. [http://dx.doi.org/10.1038/cmi.2012.2]. [PMID: 22327211]. PubMed PMC

Abaci H.E., Shuler M.L. Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. Integr. Biol. 2015;7(4):383–391. [http://dx.doi.org/10.1039/C4IB00292J]. [PMID: 25739725]. PubMed PMC

Brown J.A., Codreanu S.G., Shi M., Sherrod S.D., Markov D.A., Neely M.D., Britt C.M., Hoilett O.S., Reiserer R.S., Samson P.C., McCawley L.J., Webb D.J., Bowman A.B., McLean J.A., Wikswo J.P. Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit. J. Neuroinflammation. 2016;13(1):306. [http://dx.doi.org/10.1186/s12974-016-0760-y]. [PMID: 27955696]. PubMed PMC

Dodson K.H., Echevarria F.D., Li D., Sappington R.M., Edd J.F. Retina-on-a-chip: a microfluidic platform for point access signaling studies. Biomed. Microdevices. 2015;17(6):114. [http://dx.doi.org/10.1007/s10544-015-0019-x]. [PMID: 26559199]. PubMed PMC

Dorval T., Chanrion B., Cattin M.E., Stephan J.P. Filling the drug discovery gap: is high-content screening the missing link? Curr. Opin. Pharmacol. 2018;42:40–45. [http://dx.doi.org/10.1016/j.coph.2018.07.002]. [PMID: 30032033]. PubMed

Hachey S.J., Hughes C.C.W. Applications of tumor chip technology. Lab Chip. 2018;18(19):2893–2912. [http://dx.doi.org/10.1039/C8LC00330K]. [PMID: 30156248]. PubMed PMC

Irimia D., Wang X. Inflammation-on-a-Chip: Probing the Immune System Ex Vivo. Trends Biotechnol. 2018;36(9):923–937. [http://dx.doi.org/10.1016/j.tibtech.2018.03.011]. [PMID: 29728272]. PubMed PMC

Kodzius R., Schulze F., Gao X., Schneider M.R. Organ-on-Chip Technology: Current State and Future Developments. Genes (Basel) 2017;8(10):E266. [http://dx.doi.org/10.3390/genes8100266]. [PMID: 29019963]. PubMed PMC

Mandenius C.F. Conceptual Design of Micro-Bioreactors and Organ-on-Chips for Studies of Cell Cultures. Bioengineering (Basel) 2018;5(3):E56. [http://dx.doi.org/10.3390/bioengineering5030056]. [PMID: 30029542]. PubMed PMC

Miranda C.C., Fernandes T.G., Diogo M.M., Cabral J.M.S. Towards Multi-Organoid Systems for Drug Screening Applications. Bioengineering (Basel) 2018;5(3):E49. [http://dx.doi.org/10.3390/bioengineering5030049]. [PMID: 29933623]. PubMed PMC

Nikolic M., Sustersic T., Filipovic N. In vitro Models and On-Chip Systems: Biomaterial Interaction Studies With Tissues Generated Using Lung Epithelial and Liver Metabolic Cell Lines. Front. Bioeng. Biotechnol. 2018;6:120. [http://dx.doi.org/10.3389/fbioe.2018.00120]. [PMID: 30234106]. PubMed PMC

Rothbauer M., Rosser J.M., Zirath H., Ertl P. Tomorrow today: organ-on-a-chip advances towards clinically relevant pharmaceutical and medical in vitro models. Curr. Opin. Biotechnol. 2019;55:81–86. [http://dx.doi.org/10.1016/j.copbio.2018.08.009]. [PMID: 30189349]. PubMed

Wikswo J.P., Block F.E., III, Cliffel D.E., Goodwin C.R., Marasco C.C., Markov D.A., McLean D.L., McLean J.A., McKenzie J.R., Reiserer R.S., Samson P.C., Schaffer D.K., Seale K.T., Sherrod S.D. Engineering challenges for instrumenting and controlling integrated organ-on-chip systems. IEEE Trans. Biomed. Eng. 2013;60(3):682–690. [http://dx.doi.org/10.1109/TBME.2013.2244891]. [PMID: 23380852]. PubMed PMC

Wikswo J.P., Curtis E.L., Eagleton Z.E., Evans B.C., Kole A., Hofmeister L.H., Matloff W.J. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip. 2013;13(18):3496–3511. [http://dx.doi.org/10.1039/c3lc50243k]. [PMID: 23828456]. PubMed PMC

Wikswo J.P. Looking to the future of organs-on-chips: interview with Professor John Wikswo. Future Sci. OA. 2017;3(2):FSO163. [http://dx.doi.org/10.4155/fsoa-2016-0085]. [PMID: 28670462]. PubMed PMC

Wnorowski A., Yang H., Wu J.C. Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. 2018. PubMed PMC

Kersten K., de Visser K.E., van Miltenburg M.H., Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 2017;9(2):137–153. [http://dx.doi.org/10.15252/emmm.201606857]. [PMID: 28028012]. PubMed PMC

Uhl E.W., Warner N.J. Mouse Models as Predictors of Human Responses: Evolutionary Medicine. Curr. Pathobiol. Rep. 2015;3(3):219–223. [http://dx.doi.org/10.1007/s40139-015-0086-y]. [PMID: 26246962]. PubMed PMC

Luce S., Guinoiseau S., Gadault A., Letourneur F., Blondeau B., Nitschke P., Pasmant E., Vidaud M., Lemonnier F., Boitard C. Humanized Mouse Model to Study Type 1 Diabetes. Diabetes. 2018;67(9):1816–1829. [http://dx.doi.org/10.2337/db18-0202]. [PMID: 29967002]. PubMed

Walsh N.C., Kenney L.L., Jangalwe S., Aryee K.E., Greiner D.L., Brehm M.A., Shultz L.D. Humanized Mouse Models of Clinical Disease. Annu. Rev. Pathol. 2017;12:187–215. [http://dx.doi.org/10.1146/annurev-pathol-052016-100332]. [PMID: 27959627]. PubMed PMC

Puca L., Bareja R., Prandi D., Shaw R., Benelli M., Karthaus W.R., Hess J., Sigouros M., Donoghue A., Kossai M., Gao D., Cyrta J., Sailer V., Vosoughi A., Pauli C., Churakova Y., Cheung C., Deonarine L.D., McNary T.J., Rosati R., Tagawa S.T., Nanus D.M., Mosquera J.M., Sawyers C.L., Chen Y., Inghirami G., Rao R.A., Grandori C., Elemento O., Sboner A., Demichelis F., Rubin M.A., Beltran H. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 2018;9(1):2404. [http://dx.doi.org/10.1038/s41467-018-04495-z]. [PMID: 29921838]. PubMed PMC

Ibarrola-Villava M., Cervantes A., Bardelli A. Preclinical models for precision oncology. Biochim. Biophys. Acta Rev. Cancer. 2018;1870(2):239–246. [http://dx.doi.org/10.1016/j.bbcan.2018.06.004]. [PMID: 29959990]. PubMed

Garralda E., Paz K., López-Casas P.P., Jones S., Katz A., Kann L.M., López-Rios F., Sarno F., Al-Shahrour F., Vasquez D., Bruckheimer E., Angiuoli S.V., Calles A., Diaz L.A., Velculescu V.E., Valencia A., Sidransky D., Hidalgo M. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin. Cancer Res. 2014;20(9):2476–2484. [http://dx.doi.org/10.1158/1078-0432.CCR-13-3047]. [PMID: 24634382]. PubMed PMC

Malaney P., Nicosia S.V., Davé V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 2014;344(1):1–12. [http://dx.doi.org/10.1016/j.canlet.2013.10.010]. [PMID: 24157811]. PubMed PMC

Zayed A.A., Mandrekar S.J., Haluska P. Molecular and clinical implementations of ovarian cancer mouse avatar models. Linchuang Zhongliuxue Zazhi. 2015;4(3):30. [PMID: 26408297]. PubMed PMC

Saadat V., Tsugita R. 2005.

Wikswo J.P., Samson P.C., Emmanuel F., Reiserer R.S., Parker K.K., McLean J.A., McCawley L.J., Markov D., Levner D., Ingber D.E., Hamilton G.A., Goss J.A., Cunningham R., Cliffel D.E., McKenzie R.J., Bahinski A., Hinojosa C.D. 2017.

Gonda S.R., Chang R.C., Starly B., Culbertson C., Holtorf H.L., Sun W., Leslie J. 2013.

Gatenholm P. 2014.

Ingber D.E., Parker K.K., Hamilton G.A., Bahinski A. 2018.

Andreassen S., Falck B., Olesen K.G. Diagnostic function of the microhuman prototype of the expert system--MUNIN. Electroencephalogr. Clin. Neurophysiol. 1992;85(2):143–157. [http://dx.doi.org/10.1016/0168-5597(92)90080-U]. [PMID: 1373367]. PubMed

Animal Models in Diabetic Research-History, Presence, and Future Perspectives

Regulation of Prepro-NeuropeptideW/B and Its Receptor in the Heart of ZDF Rats: An Animal Model of Type II DM

iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

Role of Peptides in Diagnostics